We are international
Donate
• webcasts   TEXT SIZE   

'This is the most exciting ASH meeting that I've been to, and I've been a member for over 25 years.'
Morie Gertz, MD
Mayo Clinic

The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2008 annual meeting of the American Society of Hematology in San Francisco, California. We hope you will find this material informative and useful.

 print    
ASH 2008 WEBCASTS
previous     next      view all

NEWLY-DIAGNOSED: TRANSPLANT ELIGIBLE
01.04.09   Dr. Bensinger - ASH 2008 - A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington
U.S.A.
Member, IMF Board of Scientific Advisors

01.04.09   Dr. Knop - ASH 2008 - Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial
Stephan Knop, MD
University Hospital Würzburg
Würzburg, Germany

01.04.09   Dr. Kumar - ASH 2008 - Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota
U.S.A.

01.04.09   Dr. Kumar - ASH 2008 - Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota
U.S.A.

01.04.09   Dr. Kumar - Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota
USA

01.04.09   Dr. Lokhorst - ASH 2008 - Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)
Henk M. Lokhorst, MD
University Medical Center Utrecht
Utrecht, Netherlands
Member, IMF Board of Scientific Advisors

01.04.09   Dr. Palumbo - ASH 2008 - Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results
Antonio Palumbo, MD
Divisione di Ematologia dell'Università di Torino
A.O.U. San Giovanni Battista
Torino, Italy
Member,IMF Board of Scientific Advisors

01.04.09   Dr. San Miguel - Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors

01.04.09   Dr. Sonneveld - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Rotterdam, Netherlands
Member, IMF Board of Scientific Advisors

NEWLY-DIAGNOSED: ELDERLY OR NON-TRANSPLANT
01.04.09   Dr. Hajek - ASH 2008 - The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance
Roman Hajek, MD
University Hospital Brno
Brno, Czech Republic
Member, IMF Board of Scientific Advisors

previous     next      view all